F-star Therapeutics, Inc. (FSTX)
| Market Cap | 64.89M |
| Revenue (ttm) | 11.26M |
| Net Income (ttm) | -25.62M |
| Shares Out | 2.64M |
| EPS (ttm) | -9.69 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $7.13 |
| Previous Close | $8.87 |
| Change ($) | -1.74 |
| Change (%) | -19.62% |
| Day's Open | 7.10 |
| Day's Range | 6.85 - 7.90 |
| Day's Volume | 2,176,439 |
| 52-Week Range | 1.15 - 15.50 |
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (Nasdaq: FSTX) (the “Company” or “F-star”), a clinical-stage biopharmaceutical company dedicate...
SB 11285 in Combination with Radiation is More Effective than Either as Monotherapy in a Murine Tumor Model
Study Confirms F-star's Bispecific Antibody Tetravalency is the Most Efficient Way to Induce Receptor Clustering and Activation Study Confirms F-star's Bispecific Antibody Tetravalency is the Most Effic...
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 01, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next gener...
Company to Host Conference Call Today at 9 a.m. EDT Company to Host Conference Call Today at 9 a.m. EDT
Cellect Biotechnology Ltd. (NASDAQ: APOP), Immutep Limited (NASDAQ: IMMP), F-star Therapeutics, Inc. (NASDAQ: FSTX), ProQR Therapeutics N.V.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next gener...
F-star's antibody engineering platform is seemingly undervalued with comparable companies worth billions of dollars in equity value.
Patent protects Company's lead clinical asset FS118 throughout Europe Patent protects Company's lead clinical asset FS118 throughout Europe
FS222 is a potentially best-in-class bispecific antibody targeting CD137 (4-1BB) and PD-L1, and is the Company's third bispecific to enter clinical trials
CAMBRIDGE, England and CAMBRIDGE, Mass., Nov. 20, 2020 /PRNewswire/ -- F-star Therapeutics, Inc., (Nasdaq: FSTX, as of November 23, 2020) a clinical-stage immuno-oncology company determined to transform...
HOPKINTON, Mass., Nov. 20, 2020 /PRNewswire/ -- Please replace the release dated November 19, 2020 with the following corrected version due to revisions to the headline. The corrected release reads: HOP...
1-for-4 Reverse Stock Split to be Effective November 20, 2020 1-for-4 Reverse Stock Split to be Effective November 20, 2020
HOPKINTON, Mass., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncolog...
HOPKINTON, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammato...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, announces the filing of a shareholder class action lawsuit against Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) in con...
NEW YORK, Sept. 22, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Spring Bank Pharmaceuticals, Inc. ("SB...
NEW YORK, Sept. 3, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Spring Bank Pharmaceuticals, Inc.
Announced agreement for strategic combination with F-star Therapeutics to advance a pipeline of multiple clinical-stage immuno-oncology programs
NEW ORLEANS, Aug. 6, 2020 /PRNewswire/ -- Former Attorney General of Louisiana Charles C.
NEW YORK, Aug. 5, 2020 /PRNewswire/ --Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City,...
NEW YORK--(BUSINESS WIRE)-- #Acquisition--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Spring Bank Ph...
NEW YORK, July 31, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) and its board of directors violated...
NEW YORK--(BUSINESS WIRE)--Rowley Law PLLC is investigating potential securities law violations by Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) and its board of directors concerning the proposed mer...
New York, New York--(Newsfile Corp. - July 30, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To view an enhanced version of this graphic, please visit:https://orders.newsfilec...
HOPKINTON, Mass. and CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 29, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceuti...
- Safety Review Committee for IV SB 11285 Phase 1a/1b trial recommends dose escalation to next planned monotherapy dose level and initiation of first co-administration dose level with Roche’s PD-L1...
HOPKINTON, Mass., April 02, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflamm...
Spring Bank Pharmaceuticals Inc. [s; sbph] said Wednesday it is scrapping the development of inarigivir soproxil, a treatment for chronic hepatitis B virus, after a patient died during a phase 2 trial.
HOPKINTON, Mass., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of vira...
The upbeat sentiments prevailing in Wall Street make investment in small caps stocks attractive for 2020, here's why.
Spring Bank (SBPH) declines as it stops dosing and enrolling patients in phase IIb studies on inarigivir.
Spring Bank Pharmaceutical Inc.'s shares slid 17% in premarket trade Thursday, after the clinical-stage biopharma company said it has stopped dosing patients in a trial of a treatment for chronic hepat...
HOPKINTON, Mass., Dec. 26, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of vira...
Top Ranked Momentum Stocks to Buy for December 24th
As of late, it has definitely been a great time to be an investor in Spring Bank Pharmaceuticals.
Top Ranked Momentum Stocks to Buy for December 11th
HOPKINTON, Mass., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of vira...
HOPKINTON, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of vira...
HOPKINTON, Mass., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of vir...
HOPKINTON, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of vir...
As of late, it has definitely been a great time to be an investor in Spring Bank Pharmaceuticals, Inc. (SBPH).
Today, we take an in-depth look at Spring Bank Pharmaceuticals.
About FSTX
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118, is currently being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company was incorporated in 2002 and is headquartered in C... [Read more...]
| Industry Biotechnology | IPO Date May 6, 2016 |
| Stock Exchange NASDAQ | Ticker Symbol FSTX |
Financial Performance
In 2020, FSTX's revenue was $11.26 million, a decrease of -60.26% compared to the previous year's $28.32 million. Losses were -$25.62 million, 11.3% more than in 2019.
Analyst Forecasts
According to one analyst, the rating for FSTX stock is "Strong Buy" and the 12-month stock price forecast is 26.00.